Form 4: XOMA Corp Director Natasha Hernday Acquires Shares and Options

Director Natasha Hernday acquired 3,035 shares of common stock and options to purchase 4,881 shares of XOMA Corp on May 15, 2024.

Summary

• On May 15, 2024, Natasha Hernday, a director of XOMA Corp, acquired 3,035 shares of common stock in the form of restricted stock units (RSUs).
• Each RSU represents the right to receive one share of XOMA Corp common stock upon vesting, which occurs on the first anniversary of the grant date, contingent upon continued service to the company.
• Hernday also acquired a non-qualified share option to purchase 4,881 shares of common stock at an exercise price of $24.71.
• The options vest in equal monthly installments over 12 months from the grant date, with the final installment occurring on the earlier of the next annual meeting or the first anniversary of the grant date, also subject to continued service.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a director increasing their stake in the company, which is generally seen as a sign of confidence. However, it's a routine transaction and doesn't provide substantial new information.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Risks

• The vesting of the RSUs and options is contingent upon continued service, which introduces a risk of forfeiture if the director leaves the company before the vesting dates.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedules for the RSUs and options indicate a continued commitment from the director.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's value and future prospects. This transaction reflects one director's increased stake in the company.

Comparison to Industry Standards

• Stock option grants and RSU awards are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• The vesting schedules described are fairly standard, with monthly or annual vesting periods tied to continued service.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment, as it signals confidence from a company director.
• Employees may view this as a positive sign of company stability and growth potential.

Key Dates